Trial intelligence / Profile preview

Radiprodil in pediatric GRIN-related disorder

NL-OMON53530Not yet recruiting

Sponsor
GRIN Therapeutics, Inc.
Start
Feb 2023
Modality
Small Molecules
Countries
1
01

Overview

Open-label trial of radiprodil in GRIN-related disorder (3 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Adverse events, serious adverse events, and adverse drug reactions, Vital signs and 7 more. Planned start Feb 2023; status: not yet recruiting.

02

Drugs

radiprodil
03

Conditions

GRIN-related disorder

Beyond the preview

Go deeper on NL-OMON53530.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON53530.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call